Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer - Test2 - elhamkhani - TriplyDB

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

http://www.wikidata.org/entity/Q28659468

about

Regeneration of stalled immune responses to transformed and infected cells using γδ T cells What lessons can be learned from γδ T cell-based cancer immunotherapy trials?γδ T Cell Immunotherapy-A Review Immune regulation of bone metastasis Adoptive cell therapy for sarcoma γδ T cells for cancer immunotherapy: A systematic review of clinical trials Harnessing the power of Vδ2 cells in cancer immunotherapy Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme’s active site closure γδ T cells in cancer immunotherapy Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection A Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid Components A rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infections Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.Human cytomegalovirus elicits fetal gammadelta T cell responses in utero Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Immunotherapy for the treatment of prostate cancer.Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells.Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.Full restoration of Brucella-infected dendritic cell functionality through Vγ9Vδ2 T helper type 1 crosstalk.Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection.Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Targeting γδ T cells for immunotherapy of HIV disease Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.Plasticity of γδ T Cells: Impact on the Anti-Tumor Response Clinical applications of gamma delta T cells with multivalent immunity.Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18.Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire

P2860

Q26823185-1B194B56-BC3A-4CB6-B722-8F966DDBD295 Q26849323-A949EB61-A812-4BBC-9393-66E36D555AD8 Q26995102-73CDC7C3-3448-4459-B1AB-3630EF8DABE6 Q27005871-158EB3B4-DE60-417B-9681-3F86C7143284 Q27009541-9E9BAC70-26A2-4FDC-8CD0-1D35A3B75C66 Q27021705-AE775197-4275-4A37-A674-96E8276040EB Q27027547-653AC540-34E1-4935-9A2D-95A2FD2BB2AD Q27650471-D9B8BCFB-D0C0-4876-B071-7A47E6BA5868 Q27654261-961C6463-8984-4004-84ED-6BE2EB091391 Q27675453-6B66BC07-2FC6-4353-A848-569AE5AC5689 Q28068988-5BC62EC6-04DA-4454-9912-3022FB1D8008 Q28535348-4E54B8DC-F58D-423C-B3E4-4543D93C0012 Q28729744-E6778C30-667A-4DB4-BCA0-1D7AEE18616E Q28829233-276DABC2-6663-45A5-B854-2D4C1C8146E9 Q33410795-3D028578-9FD5-4033-A814-A699451163C7 Q33455830-0FD9FB0F-01C7-4F25-B47E-4EB410E1DEE2 Q33795023-6BF8FBE2-7C96-4F95-AD77-14BD27DC50B4 Q33903025-DEC252A4-5AB7-4064-A1FC-2E3E2AF12434 Q33905819-E65CDCA2-3D44-41FA-8FEC-4AB639851FEE Q33920919-85F43CEA-9F91-4EB7-84B3-87FB1682883C Q34145863-16BD7AB8-6B24-4902-8B84-720315F49F54 Q34186928-AA69F62C-6869-41CD-8DAF-8EBF10F139DE Q34249937-231C0E2B-7F80-4AA1-AA0E-7F9458DD2C49 Q34395222-6FFCF2BB-5013-44F2-86E3-CBA7048BD82F Q34395849-F57FA48A-6376-4972-90FC-28ABE650EF6C Q34493921-970FC481-9169-4FF9-A1ED-F804BDF94F44 Q34496948-48944434-2590-400E-9463-6DDFABCA8310 Q34560345-ECB8661E-122C-4088-9796-5F257734C17D Q34585223-EA2AAC62-13FF-4D8F-A6FF-461FF40B85DF Q34595188-E34F5C18-0502-430C-A98E-6F7B16DB5F6A Q34612619-C7E75183-E4E1-40B9-B8BA-8769C8E48B40 Q34652408-2D820DC0-DFD2-4D53-A4C4-F9009FB1F9A2 Q34677859-54C2C0C3-D018-40AB-8515-13A9A6D89237 Q34681370-5FF3927F-EA61-4627-8E0A-3966B2116267 Q34743969-73E35C6F-26CC-40B4-ADDA-B725D29D0041 Q34749889-C64F58EE-D235-4678-9371-8BBB68BD8E1D Q34802235-D2F1D9BC-8C9D-4CFD-8883-7451743AE50F Q34939979-B7AC9528-4F47-4338-8BF5-2EDFA5B1F861 Q35077632-8D05B7AA-9AF8-4A19-8469-BA9E6675C991 Q35090079-0FD4D82F-90B8-4503-9F7B-592A745A7D94

P2860

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

http://www.wikidata.org/entity/Q28659468

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@ast

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@en

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@nl

type

label

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@ast

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@en

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@nl

prefLabel

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@ast

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@en

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@nl

P1433

Q28659468-170F4900-030C-4294-9B24-7B574E72A80C

P1476

Q28659468-1692B6FB-B5BA-4812-BDAB-69CE3274D1E1

P2093

Q28659468-07BEFF16-F8B7-444A-8E0D-915146FD0971

Q28659468-158AAB4C-9713-4CE8-A32C-FFD9534287AF

Q28659468-300B4A4C-D092-4957-BF8A-D9BFD0F22747

Q28659468-4D8BE288-99A5-4910-8872-CC14698C5E4B

Q28659468-8349800E-3165-4985-B8A0-0E6E60F737BA

Q28659468-9FB29D86-D65F-4058-8EE2-FAE0CCE47942

Q28659468-FC1060FF-DC33-4730-982E-2E629D90D378

P2860

Q28659468-12961C3C-7B13-4AE0-B272-9DDF6DC91E26

Q28659468-12F80F88-1711-4746-9C38-465F217D2941

Q28659468-1652B86B-31F1-40A7-8DA0-5F777FB57984

Q28659468-1897BDF4-A84A-408D-90B3-B66EA9A4A091

Q28659468-1D279E54-92E0-4D42-B6BA-D0A0BB7942AB

Q28659468-1F203139-85D8-4602-A441-2D092662F9E9

Q28659468-2CD9CC4D-818B-4CD7-99BB-76703F87AE6A

Q28659468-2F4C5F6A-5B2F-4E5E-A63A-30D51E0CAC45

Q28659468-33B7514F-EEDA-4183-8AF7-92BFE66C4AF8

Q28659468-43028A60-1C0E-4E3B-8A35-1FE21045243C

P304

Q28659468-2E7EFA53-A726-4EE3-9378-BDD0D8A360E1

P31

Q28659468-5340898F-CFB6-49FF-89DE-1561FF095C84

P3181

Q28659468-A89F603C-235E-43D6-A900-A3E4AEB60E5A

P356

Q28659468-649AC83F-411E-4F32-8BB2-886FADE59ED5

P407

Q28659468-58BBFB6C-8B24-409E-852E-2DA300E84D4B

P433

Q28659468-E7A353E9-9E62-4F3B-814C-1B768185A2A8

P478

Q28659468-6DE4C254-6568-47E1-ADF7-4487A10DA209

P50

Q28659468-04ADDA97-3A6F-4FC5-9807-B8985A78FB7F

Q28659468-7BDCF46D-443C-480C-A45A-7716B1E76F48

Q28659468-9A832E86-D916-43D9-A450-00F6F2BCAEA2

Q28659468-B8D3851D-A1E2-4986-AF16-A740EA4D1C95

Q28659468-CA39978B-E7D4-49CE-A637-0922A47A7334

Q28659468-D25AEBC5-6BD8-4753-B226-4AB719941B20

P577

Q28659468-F056C6AD-FFBB-47A5-9E31-436570A69118

P698

Q28659468-8874391D-9933-434B-B479-7C6631226573

P921

Q28659468-68bbf4de-f1d7-48aa-96a3-7b3f37bcf032

Q28659468-8B62E12C-1846-45E7-BEB1-1E3675E15330

P932

Q28659468-3F4A376F-B2CC-42E9-BE83-D3E15EAEA421

P3181

P356

0008-5472.CAN-07-0199

P1433

Cancer Research

P1476

Targeting human {gamma}delta} ...... one-refractory prostate cancer

@en

P2093

Alfredo Salerno

http://www.w3.org/2001/XMLSchema#string

Andrew Roberts

http://www.w3.org/2001/XMLSchema#string

Fabio Fulfaro

http://www.w3.org/2001/XMLSchema#string

Matilde D'Asaro

http://www.w3.org/2001/XMLSchema#string

Nicola Gebbia

http://www.w3.org/2001/XMLSchema#string

Serena Meraviglia

http://www.w3.org/2001/XMLSchema#string

Simona Buccheri

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: building on success

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Antigen recognition by human gamma delta T cells: pattern recognition by the adaptive immune system

Regulation of cutaneous malignancy by gammadelta T cells

Microbial isoprenoid biosynthesis and human gammadelta T cell activation

APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy

Cancer statistics, 2005

Natural history of progression after PSA elevation following radical prostatectomy.

Role of gammadelta T cells in tumor immunity and their control by NK receptors.

Effector memory T cells, early metastasis, and survival in colorectal cancer.

P304

7450-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1512497

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-07-0199

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Adrian Clive Hayday

Francesco Dieli

David Vermijlen

Giuseppe Cicero

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17671215

http://www.w3.org/2001/XMLSchema#string

P921

P932

3915341

http://www.w3.org/2001/XMLSchema#string